Grilled Cheese

ExploreLog inSign up

American Journal of Kidney Diseases

@ajkd.bsky.social

676 Following3.2k Followers

AJKD, official journal of @kidney.org, is the leading source of information devoted to clinical nephrology research and practice. AJKD.org | AJKDblog.org | Organizer of #NephMadness @nephmadness.bsky.social

PostsRepliesMedia
@ajkd.bsky.socialOct 8, 2026, 10:00 PM

The Nephrologist’s Guide to Lower Urinary Tract Conditions: A Urology-Based Review

bit.ly/4bX1zK5 (FREE)

Urodynamics testing environment.
@ajkd.bsky.socialOct 8, 2026, 4:02 PM

Commentary by Natasha Freeman on the #AJKDBlog:

A Call for Better Cancer Screening Guidelines for Patients with Glomerular Disease

bit.ly/4A5ziLx

@ajkd.bsky.socialOct 8, 2026, 10:02 AM

Steroid Minimization in Kidney Transplantation: Rationale, Implementation, and Future Directions

bit.ly/4glCtqP

Key challenges and knowledge gaps in steroid minimization after kidney transplantation. This conceptual framework summarizes the principal clinical and methodological challenges associated with steroid minimization and early steroid withdrawal strategies. Four key domains are highlighted: (A) balancing metabolic benefits against immunologic risk, (B) defining appropriate candidates in the setting of heterogeneous immunologic risk profiles, (C) protocol and center-level variability in definitions, timing, and induction strategies, and (D) limitations of current precision tools for monitoring and risk stratification. At the center is the need to balance immunologic safety with metabolic benefit when considering steroid minimization. Collectively, these domains underscore variability in practice patterns, uncertainty in patient selection, and limitations in current monitoring approaches, all of which contribute to heterogeneity in outcomes and limit standardization across centers.
@ajkd.bsky.socialOct 7, 2026, 10:00 PM

Platelet Reactivity Expression Score and Major Adverse Cardiovascular and Limb Events in CKD

bit.ly/4xu47Ii

Association between CKD and PRESS. (A) Distribution of PRESS z score by CKD status. (B) Distribution of PRESS z score by CKD severity. (C) Correlation between PRESS z score and eGFR. (D) Kaplan-Meier curves for freedom from MACLE stratified by PRESS and CKD status. (E) Risk of MACLE by PRESS and CKD status. Abbreviations: ANOVA, analysis of variance; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; MACLE, major adverse cardiovascular and limb events; PRESS, Platelet Reactivity Expression Score.
@ajkd.bsky.socialOct 7, 2026, 4:01 PM

EDITORIAL: Bloodless Potassium: Can Artificial Intelligence–Enabled Electrocardiography Guide Both Acute Detection and Correction of Hypokalemia?

bit.ly/4yCxmt1

@ajkd.bsky.socialOct 7, 2026, 10:00 AM

Distribution of GFR in Apparently Healthy Indians

bit.ly/4qy4T4n

Measured glomerular filtration rate (mGFR) of apparently healthy Indian subjects is shown for various ages compared to the mGFR of apparently healthy individuals from the European population. Red lines: Median and 2.5th and 97.5th regression quantiles based on second-degree polynomials for Indian apparently healthy subjects.
@ajkd.bsky.socialOct 6, 2026, 10:01 PM

An Interactive Virtual Nephrologist to Engage Patients With Advanced CKD About Transplantation

bit.ly/4z0Bjbg (OPEN ACCESS)

@ajkd.bsky.socialOct 6, 2026, 4:04 PM

Blood Leak Alarms With Hydroxocobalamin Administration

bit.ly/4dq6cgp

 Suggested algorithms for handling blood leak alarms derived from our institution’s protocol: (A) if blood is visualized; (B) if blood is NOT visualized.
@ajkd.bsky.socialOct 6, 2026, 10:00 AM

The October 2026 issue of AJKD is available now!

Check out the plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters:

bit.ly/46V3wDR

@ajkd.bsky.socialOct 5, 2026, 10:02 PM

Hospitalizations With Pericarditis and Pericardial Effusions in People With Kidney Failure Receiving Dialysis in the United States (2016-2021)

bit.ly/4qiSS2s

@winkeldoc

Annual totals and rates of hospitalizations for pericarditis/pericardial effusions for the US prevalent dialysis population, 2016-21 in which cardiac tamponade or cardiogenic shock were present. Notes: Numbers are estimates using the National Inpatient Sample (Panel A), and from both the National Inpatient Sample and the 2023 Annual Data Report of the United States Renal Data Service (Panel B).8 Dotted lines represent 95% confidence intervals.
@ajkd.bsky.socialOct 5, 2026, 4:01 PM

The ‘Known Unknowns’ of CKD of Undetermined Etiology In 2026

bit.ly/4ebVfPG (OPEN ACCESS)

Burden of low eGFR in working-age rural males without hypertension, diabetes or heavy proteinuria. Age-standardised estimates in the 18–60-year-old population from the DEGREE collaboration. Released under a CC BY 4.0 license from Rutter et al.
@ajkd.bsky.socialOct 5, 2026, 10:00 AM

Risks of Postpartum Kidney Disease Following Preeclampsia and Gestational Hypertension

bit.ly/4wf6TQ3 (OPEN ACCESS)

Association of preeclampsia with and without severe features compared to gestational hypertension 0-29, 30-59, 60-89, 90-179, 180-365 days after delivery for any acute kidney injury and chronic kidney disease (confounder-adjusted hazard ratio with 95% CI), Nationwide Readmissions Database, 2010 to 2020
@ajkd.bsky.socialOct 4, 2026, 10:00 PM

On the #AJKDBlog:

@maximalchange.bsky.social interviews Niraj B. Desai, Casey Gashti, and @nephrowhitt.bsky.social about the history of lupus nephritis and several exciting new therapies:

@ajkd.bsky.socialOct 4, 2026, 4:00 PM

The October 2026 issue of AJKD is available now!

Check out the plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters:

bit.ly/46V3wDR

@ajkd.bsky.socialOct 4, 2026, 10:00 AM

An Unexpected Cause of Early Allograft Dysfunction: A Quiz

bit.ly/3VsIn1f (FREE)

@ajkd.bsky.socialOct 2, 2026, 10:00 PM

NEW Blog Interview from Timothy Yau and Ikechi G. Okpechi on the #AJKDBlog:

Chronic Kidney Disease Prevalence in Africa

bit.ly/4xQzuvP (FREE)

@ajkd.bsky.socialOct 2, 2026, 4:01 PM

A Perspective on the Role of Nephrologists in the Cardio-Kidney-Metabolic Syndrome

bit.ly/47vv4jd (OPEN ACCESS)

The roles for nephrologists within the CKM Framework across the spectrum of kidney diseases. The outer rim represents distinct subs-specialties within which nephrologists may integrate the CKM framework and vice-versa. Abbreviations: AKI= acute kidney injury; AKD = acute kidney disease; CKD = Chronic Kidney Disease; CKM = Cardiac Kidney Metabolic
@ajkd.bsky.socialOct 2, 2026, 10:00 AM

Perceptions of Hispanic Patients with Advanced CKD About Communication and Engagement Regarding Kidney Transplantation: A Qualitative Study

bit.ly/4g7lPLn

Interview themes overlaid on Berlo’s framework. The Berlo’s communication framework views communication as the transfer of information and includes four components: the source or sender, the message or encoding of the message, channel or the delivery method of the message, and the receiver of the message. This figure overlays linguistic context, conversational context, socioemotional context and informational context on the Berlo’s framework to depict the main themes identified in the interviews.
@ajkd.bsky.socialOct 1, 2026, 10:01 PM

Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study

bit.ly/4whjJON (OPEN ACCESS)

@ajkd.bsky.socialOct 1, 2026, 4:02 PM

Application of a Kidney Hierarchical Composite Endpoints in Trials of CKD Progression: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

bit.ly/4z8VeUR

Illustration of the analysis of a hierarchical composite endpoint. In a hypothetical trial, 6 participants are assigned to active treatment (A) or control group (C) and followed for a hierarchical composite endpoint of death (most clinically important) or kidney failure (Panel A). Each participant assigned to active treatment is compared to each assigned to the control group in a pairwise manner (Panel B). For each pairwise comparison, the most clinically important outcome that occurs during shared follow-up time is used to determine whether the participant assigned to active therapy has a better outcome (“win”), worse outcome (“loss”) or “tie” (Panel C). For example, participant A1 was alive when participant C1 died (a “win”) but died while participants C2 and C3 were alive (“losses”). Participant A2 was alive when participant C1 died (a “win”), reached kidney failure after participant C2 (with neither participant dying, a “win”), and reached kidney failure at the same time as partici
Older posts
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-11 02:37:10 EDT